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Abstract
 Purpose of the review—The purpose of this review is to summarize recent advances in the 
development of nucleic acid-based biomarkers in type 1 diabetes (T1D).
 Recent findings—Recent rodent and human studies have identified new roles for stress 
pathways intrinsic to the β cell during the development of T1D. As such, methods to identify an 
authentic nucleic acid signature of β cell stress and/or death may improve our ability to predict 
T1D at earlier timepoints, allowing for optimal timing of immunomodulatory interventions. To 
this end, both targeted and unbiased approaches have begun to identify changes in microRNA 
expression patterns in T1D. Moreover, a number of groups have developed distinct assays that 
quantitatively detect circulating unmethylated insulin DNA, which is thought to primarily emanate 
from dying β cells.
 Summary—Here we highlight unique blood and urine miRNA signatures identified in T1D 
cohorts, compare differences between first, second, and third generation assays that detect 
circulating unmethylated insulin DNA, and review recent technological advances that have the 
capacity to improve T1D biomarker development.
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Since 1994, over 260,000 persons have undergone screening to identify cohorts of 
individuals at risk of developing Type 1 diabetes either as part of the Diabetes Prevention 
Trial of Type 1 Diabetes (DPT-1) or TrialNet Pathway to Prevention Initiatives. From these 
efforts, nearly 2000 autoantibody positive or diabetic individuals have participated in NIH-
sponsored trials that have tested the ability of immunomodulatory therapies to preserve β 
cell function in established or pre-clinical T1D. Four agents have shown efficacy in 
preserving C-peptide secretion and these include a monoclonal antibody against CD20 
(rituximab), monoclonoal antibodies against CD3 (tepluzimab), CTLA4-lg-mediated co-
stimulatory blockade with abatacept, and alefacept, a fusion protein that binds CD2, and 
targets CD4+ and CD8+ effector memory T cells (1–6). However, the degree of preservation 
of β cell function afforded by these drugs has been modest. To date, a therapeutic regimen 
capable of robustly inducing immune tolerance or insulin independence has not yet been 
identified. In part, the inability of these treatments to dramatically modify T1D progression 
may be related to the timing of interventions, since irreparable damage to the β cell pool has 
already been firmly established by the time of T1D presentation and clinical recognition (7). 
One potential solution has been to target at-risk individuals before the onset of clinical 
disease. To this end, oral insulin, abatacept, and tepluzimab are currently being tested in pre-
diabetic auto-antibody subjects enrolled in the Type 1 Diabetes TrialNet Pathway to 
Prevention Cohort. However, to support these efforts, there remains an unmet clinical need 
centered around improving our ability to more precisely predict risk in the pre-diabetic 
phase of T1D. Addressing this roadblock represents a critical step towards the development 
of personalized approaches to T1D prevention and/or reversal.
A number of immune variables including autoantibody (AAb) positivity, HLA status, and T 
cell signatures have been used to stratify risk (8–10). In clinical trials, measures of β cell 
function, such as loss of the early insulin response during intravenous or oral glucose 
tolerance test (OGTT) or changes in the integrated secretion of C-peptide during an (OGTT) 
have been utilized to document metabolic decompensation (11). However, these paradigms 
may either fail to reliably differentiate T1D progressors from non-progressors or are 
cumbersome to measure. Recently, rodent and human studies have begun to identify an 
increasing role for stress pathways intrinsic to the β cell during the development of type 1 
diabetes (12, 13). These data suggest that processes such as β cell calcium dyshomeostasis, 
misfolded protein accumulation, oxidative stress, and endoplasmic reticulum stress become 
activated early during the evolution of T1D and act to either initiate or augment autoimmune 
mediated β cell death and dysfunction (14–17). Thus, directed methods to identify an 
authentic signature of β cell stress and/or death based on activation of these stress pathways 
may augment our ability to optimally time immunomodulatory interventions. Here, we 
highlight recent efforts aimed at the specific identification of nucleic acid biomarkers that 
may provide insight into the health of the β cell, focusing on microRNA signatures in type 1 
diabetes and cell-free DNA based methodologies to measure β cell death.
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 Differentially expressed miRNAs in type 1 diabetes
MicroRNAs (miRNAs) are a class of small non-coding RNAs that play a central role in the 
regulation of gene expression. In mammals, miRNAs are generally considered to be negative 
regulators of gene expression, acting either through translational repression of target mRNAs 
or by decreasing mRNA stability (18). However, in select cases, miRNAs are also involved 
in the upregulation of certain mRNAs (19, 20). Currently, upwards of 1800–2000 known 
human miRNAs have been identified, and it is estimated that miRNAs regulate ~60% of 
protein-coding genes (21). As such, a role for miRNAs has been demonstrated in a wide 
variety of biological processes, including development, proliferation, differentiation, cell 
signaling and cell death. In recent years, several specific miRNAs have also been shown to 
play important roles in both the regulation of β cell function and the pathogenesis of Type 1 
diabetes (22). Although, miRNAs are intracellular origin, they may also be secreted 
extracellularly, either through microvesicles or exosomes, which can then be taken up by 
different cells to influence their gene expression patterns (23–25). Compared to mRNA 
species, miRNAs are invariably more stable in biological fluids, where they have been 
detected in high abundance in blood, urine, saliva, cerebrospinal fluid, milk, seminal fluid, 
and amniotic fluid (26). Thus, the identification of circulating miRNAs as biomarkers of 
specific disease processes is an area of active and intense research.
miRNA-375 is considered to be one of the most abundant miRNAs expressed in the β-cell. 
Early studies by Poy et al., demonstrated that overexpression of miR-375 in MIN6 cells and 
primary mouse islets inhibited glucose-stimulated insulin secretion, independent of changes 
in glucose metabolism and Ca2+ signaling (27). Interestingly, mice lacking miR-375 were 
later found to be hyperglycemic as a result of decreased β-cell mass, increased alpha cell 
number, and increased glucagon secretion (28). Given the abundance of this miRNA in the β 
cell, a role for miR-375 as a diabetes biomarker has also been explored. Elevated plasma 
miR-375 levels have been demonstrated in streptozotocin-treated mice as well as in non-
obese diabetic mice prior to the onset of hyperglycemia (29). Human subjects undergoing 
autologous and allogeneic islet transplantation were found to have elevated levels of 
miR-375 in plasma samples 7 days after transplantation (30). Moreover, Latrielle et al found 
that plasma miRNA-375 levels were elevated in C-peptide negative human subjects with 
Type 1 diabetes. However, this group also showed that β cell-derived miRNA-375 only 
contributes to about 1% of the total pool of circulating miRNA-375. Thus, while these 
authors speculated that increases in miR-375 may provide a reasonable assessment of β cell 
death, they questioned whether miRNA-375 was capable of providing insight into levels of β 
cell mass (31).
Unbiased approaches to identify other relevant miRNA species involved in the islet or β cell 
response to diabetic stress and T1D pathogenesis has also been undertaken. Data from 
global microarray profiling of human islets treated with a cocktail of pro-inflammatory 
cytokines documented increases in miR-21, miR-34a, and miR-146a. These miRNAs were 
also found to be increased in islets of NOD mice prior to the onset of hyperglycemia (32). In 
a subsequent study, the same group performed microarray profiling of islets from pre-
diabetic NOD mice and found increased expression of miR-29a/b/c (33).
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Comprehensive sequencing analysis of the serum miRNA profiles of subjects with new 
onset T1D has also revealed differential expression of multiple miRNAs (22). Nielsen and 
coworkers used global miRNA sequencing analysis to compare pooled sera from two 
cohorts of pediatric subjects who had been newly diagnosed with T1D within the past month 
and compared results to a healthy control group. After targeted PCR verification and 
adjustment for age and sex, the group identified a signature of 12 differently expressed 
miRNAs in T1D subjects, which included mi52, miR-30a-5p, miR-181a, miR-24, miR-148a, 
miR-210, miR-27a, miR-29a, miR-26a, miR-27b, miR-25, and miR-200a. Interestingly, 
miR-25 was found to be negatively correlated with HbA1c one month after T1D diagnosis 
and positively correlated with stimulated C-peptide levels measured three months after 
diagnosis (34). A recent study by Osipova et.al. investigated circulating levels of three 
specific miRNAs, miR-21, miR-126 and miR-210, in plasma and urine samples of subjects 
with established T1D using quantitative RT-PCR. Compared to age-matched non-diabetic 
controls, levels of miR-21 and miR-210 were significantly increased in plasma and urine 
samples of subjects with T1D, while miR-126 was decreased in urine from subjects with 
T1D. Levels of urine miR-126 were also found to be negatively correlated with glycemic 
control (35).
Studies have also analyzed miRNA expression patterns the immune cell. fraction in 
individuals with T1D. Sebastiani and colleagues found that expression of miR-326 was 
increased in lymphocytes isolated from a small cohort of auto-antibody positive subjects 
with T1D compared to auto-antibody negative subjects with T1D (36). Similarly, Yang and 
colleagues identified miRNAs that were differentially expressed in PBMCs from subjects 
with new onset T1D compared to non-diabetic controls. This analysis identified 26 
differentially expressed microRNAs. MiR-146 was identified as the mostly significantly 
changed and levels of miR-146 were decreased by nearly 50% in PBMCs from persons with 
T1D (37).
 Differently methylated β-cell derived DNA as a type 1 diabetes biomarker
The recent identification and characterization of cell-free DNA in bodily fluids and has also 
emerged as a promising and non-invasive method for disease monitoring, and this approach 
typically utilizes information regarding the methylation status of a specific gene of interest. 
DNA methylation occurs through the addition of a methyl group to a cytosine-guanine 
(CpG) dinucleotide and serves to either silence or promote gene expression in a specific cell 
type (38). In cells where a gene is highly expressed, the promoter and coding regions are 
primarily unmethylated. Conversely, in cells where a specific gene is quiescent, the promoter 
tends to be hypermethylated. Changes in patterns of DNA methylation may be observed 
during development, entry into cell cycle, aging, as part of disease pathogenesis, and during 
cell death (39, 40). The use of cell-free DNA as a diagnostic biomarker was pioneered in the 
cancer field, where cancer cells have been found to exhibit aberrant DNA methylation 
patterns in oncogenes (41).
In an idea first proposed by Akirav and Herald, the use of assays that detect circulating cell-
free DNA has been extended to the field of T1D (42). To date, these efforts have focused on 
the detection of circulating unmethylated insulin DNA and take advantage of the fact that 
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certain CpG sites in the insulin gene (Ins1/Ins2 in mice and INS in humans) are specifically 
unmethylated in pancreatic β-cells and highly methylated in most other tissues (43) Hence, 
as β-cells die during the evolution of T1D, it is presumed that increased unmethylated 
insulin DNA emanates from the β-cell and is detectable in the circulation. First generation 
assays to detect β-cell derived unmethylated insulin DNA were performed using a nested 
PCR approach, where isolated DNA from serum or plasma was subjected to bisulfite 
conversion, followed by a methylation insensitive PCR amplification step, manual extraction 
of the PCR product from a gel, followed by a methylation specific PCR step (42, 44, 45). 
The major limitation of these methods included potential non- specific amplification of non-
target sequences, high background signals, and the inability to perform these assays in a 
high-throughput manner outside of the research setting.
Second-generation insulin (INS) DNA assays have taken advantage of methylation specific 
multiplex PCR assays targeting multiple CpG sites on the insulin gene as well as highly 
sensitive droplet digital PCR-based detection techniques. Indeed, these methodologies 
appear to have led to improved sensitivity and reduced non-specific background 
amplifications. Using an assay that detects two distinct methylation-sensitive sites of the 
human insulin gene at positions +396 and +399 from the transcriptional start site (46), 
Herold and colleagues showed that autoantibody positive at-risk individuals who progressed 
to type 1 diabetes while being followed in the TrialNet Pathway to Prevention study had 
higher ratios of unmethylated/methylated INS DNA compared to healthy control subjects. 
Furthermore, the ratio of unmethylated/methylated INS DNA was associated with alterations 
in the insulin secretory pattern (47). Fisher et al reported on a droplet digital PCR based 
assay targeting differences in the methylation status of the −69 bp position of human INS 
DNA and showed that pediatric subjects with new onset T1D had higher circulating levels of 
both methylated and unmethylated insulin DNA compared to age, gender, and weight 
category matched non-diabetic control individuals (48).
An important distinction between these two assays has centered around normalization 
methods. The Herold group reports data as a ratio of unmethylated/methylated insulin DNA, 
while the Mirmira groups reports values for the methylated and unmethylated probes 
individually. Consistent with the idea that levels of methylated INS DNA may also change 
dynamically with disease, Fisher and colleagues found that both unmethylated and 
methylated INS DNA levels were elevated in individuals with new-onset T1D. However, at 8 
weeks after T1D diagnosis, levels of the unmethylated INS DNA decreased but methylated 
INS DNA levels remained elevated. At present, it remains unclear to what extent each 
species might be independently informative of the underlying disease process. Furthermore, 
it is not clear precisely which cell populations contribute to circulating levels of methylated 
INS DNA. Interestingly, a recent report showed that the methylation status of the insulin 
gene in the β cell becomes progressively more methylated in the non-obese diabetic (NOD) 
mouse model during the evolution of T1D. These data would suggest that increased levels of 
methylated INS DNA may also be informative of ongoing β cell death (49).
Yet another distinct approach, or a third generation assay, has been recently described by the 
Dor group. This approach was predicated on global assessment of tissue specific DNA 
methylation patterns identified from an Illumina Infinium Human Methylation 450 Bead 
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Chip array or obtained from publicly available methylome databases. Next, regional tissue-
specific patterns of methylation were characterized based on assessment of the methylation 
status of a CpG marker site combined with the assessment of 4–9 additional CpG sites 
adjacent to the original marker site. This information was used to design assays that utilized 
DNA sequencing to quantify the methylation status of a particular region of interest in a 
tissue specific manner. By example, an assay to detect β cell derived DNA interrogates the 
methylation status of 6 CpG sites across the insulin promoter region. Using this approach, 
the authors found that demethylation at all 6 sites was present in ~80% of DNA molecules 
from β cells compared to less than 0.01% of DNA from other tissues. As proof of principle, 
samples from persons with recent onset T1D were analyzed, and results compared to healthy 
controls. The fraction of circulating cell-free DNA in plasma from persons with new onset 
T1D was 1.9–5.5%, compared to 0.12% in healthy controls (50).
 Conclusion: Current roadblocks for robust biomarker development: 
Charting a path forward
While encouraging progress have been made towards the identification of a miRNA 
signature of Type 1 diabetes and the development of cell-free DNA assays that detect β cell 
death, additional refinements are still needed to translate these findings into clinical practice. 
With a few exceptions, the majority of studies described in this review have utilized cross-
sectional analyses of clinical cohorts. Future studies focused on identifying longitudinal 
changes in biomarker panels in at-risk or autoantibody positive pre-diabetic subjects will 
likely yield critical new information regarding elevations of biomarkers prior to the onset of 
clinically detectable T1D. Likewise, efforts to identify novel biomarkers will also be 
enhanced by technological advancements. For example, Joshi et al recently described the use 
of label free plasmonic biosensors for detection of circulating miRNAs in plasma samples of 
subjects with pancreatic ductal adenocarcinoma. This technique does not require RNA 
extraction and reportedly measures miRNAs levels in the attomolar range (51). Moreover, 
the identification of exosomes derived specifically from the β cell may increase the 
sensitivity and specificity of this approach. However, at present, techniques to sort β cell 
specific exosomes do not exist.
In addition to further refinements focused on detection of circulating INS DNA, the use of 
methylation specific probes to detect genes other than the insulin gene should increase both 
the sensitivity and specificity of this approach. Such an approach will require the rigorous 
and unbiased identification of other genes that are differentially methylated in the pancreatic 
β cell compared to non β cells. However, these efforts will also need to consider dynamic 
changes in methylation patterns that occur as part of T1D pathogenesis.
Recently, Snyder and colleagues performed deep sequencing of circulating cell-free DNA to 
develop genome-wide maps of nucleosome occupancy. In healthy individuals, their analysis 
showed that the circulating nucleosome footprint most closely matched cells of 
hematopoietic lineage. These results were then compared to the maps obtained from a small 
group of individuals with advanced malignancy. Interestingly, their analysis showed that 
patterns of nucleosome spacing in these individuals revealed contributions to the cell-free 
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DNA pool that differed from healthy individuals and closely matched the origin of that 
individual’s underlying cancer. This methodology may provide a second method that could 
be used to infer cells of origin for cell-free DNA analysis (52). However, whether this 
method could similarly be applied to type 1 diabetes remains to be tested.
In summary, the identification of a robust signature of β-cell stress and death that can be 
used to accurately predict T1D and guide therapeutic choices remains elusive. Success in 
this endeavor will most likely require the use of composite biomarker panels that incorporate 
clinical information, nucleic acid biomarkers discussed here and protein, metabolomics, and 
lipidomic signatures. While continued discovery efforts will be required, is important that 
such discovery does not continue in isolation, and efforts to integrate these diverse dataset is 
rapidly pursued.
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1. MicroRNAs are stable in a variety of biological fluids. Unique serum 
and urine microRNA signatures have been described in human Type 1 
diabetes cohorts, suggesting their potential utility as biomarkers of β 
cell stress and death.
2. Quantitative methods to measure β cell-derived cell free DNA in 
plasma or serum may help identify β cell destruction in Type 1 
diabetes. Recent efforts have focused on the refinement of assays that 
detect circulating levels of unmethylated insulin DNA.
3. The accurate prediction of β cell stress and death in Type 1 diabetes 
will likely require the use of composite biomarker panels that 
incorporate a variety of nucleic acid species.
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